Cargando…

Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth

IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Korac, Ksenija, Rajasekaran, Devaraja, Sniegowski, Tyler, Schniers, Bradley K., Ibrahim, Andrew F., Bhutia, Yangzom D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472820/
https://www.ncbi.nlm.nih.gov/pubmed/35997090
http://dx.doi.org/10.1042/BCJ20210851
_version_ 1784789374538350592
author Korac, Ksenija
Rajasekaran, Devaraja
Sniegowski, Tyler
Schniers, Bradley K.
Ibrahim, Andrew F.
Bhutia, Yangzom D.
author_facet Korac, Ksenija
Rajasekaran, Devaraja
Sniegowski, Tyler
Schniers, Bradley K.
Ibrahim, Andrew F.
Bhutia, Yangzom D.
author_sort Korac, Ksenija
collection PubMed
description IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cells also overexpress IDO1. Immunotherapy targeting IDO1 has been one of the focus areas in cancer biology, but lately studies have identified non-immune related functions of IDO1 leading to a paradigm shift with regard to IDO1 function in the context of tumor cells. In this study, we show that PDAC tissues and PDAC cells overexpress IDO1. The expression level is reciprocally related to overall patient survival. We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. Using athymic nude mice, we demonstrate that carbidopa-mediated suppression of IDO1 expression attenuates tumor growth. Mechanistically, we show that AhR is responsible for carbidopa-mediated suppression of IDO1, directly as a transcription factor and indirectly by interfering with the JAK/STAT pathway. Overall, targeting IDO1 not only in immune cells but also in cancer cells could be a beneficial therapeutic strategy for PDAC and potentially for other cancers as well and that carbidopa could be repurposed to treat cancers that overexpress IDO1.
format Online
Article
Text
id pubmed-9472820
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-94728202022-09-19 Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth Korac, Ksenija Rajasekaran, Devaraja Sniegowski, Tyler Schniers, Bradley K. Ibrahim, Andrew F. Bhutia, Yangzom D. Biochem J Cancer IDO1 is an immunomodulatory enzyme responsible for tryptophan catabolism. Its expression in immune cells, especially the DCs, has attracted attention because it leads to tryptophan depletion at the immunological synapse, thereby causing T-cell anergy and immune evasion by the tumor cells. Cancer cells also overexpress IDO1. Immunotherapy targeting IDO1 has been one of the focus areas in cancer biology, but lately studies have identified non-immune related functions of IDO1 leading to a paradigm shift with regard to IDO1 function in the context of tumor cells. In this study, we show that PDAC tissues and PDAC cells overexpress IDO1. The expression level is reciprocally related to overall patient survival. We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. Using athymic nude mice, we demonstrate that carbidopa-mediated suppression of IDO1 expression attenuates tumor growth. Mechanistically, we show that AhR is responsible for carbidopa-mediated suppression of IDO1, directly as a transcription factor and indirectly by interfering with the JAK/STAT pathway. Overall, targeting IDO1 not only in immune cells but also in cancer cells could be a beneficial therapeutic strategy for PDAC and potentially for other cancers as well and that carbidopa could be repurposed to treat cancers that overexpress IDO1. Portland Press Ltd. 2022-09-06 /pmc/articles/PMC9472820/ /pubmed/35997090 http://dx.doi.org/10.1042/BCJ20210851 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) . Open access for this article was enabled by the participation of Texas Tech University Health Sciences in an all-inclusive Read & Publish agreement with Portland Press and the Biochemical Society Center.
spellingShingle Cancer
Korac, Ksenija
Rajasekaran, Devaraja
Sniegowski, Tyler
Schniers, Bradley K.
Ibrahim, Andrew F.
Bhutia, Yangzom D.
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
title Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
title_full Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
title_fullStr Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
title_full_unstemmed Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
title_short Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
title_sort carbidopa, an activator of aryl hydrocarbon receptor, suppresses ido1 expression in pancreatic cancer and decreases tumor growth
topic Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472820/
https://www.ncbi.nlm.nih.gov/pubmed/35997090
http://dx.doi.org/10.1042/BCJ20210851
work_keys_str_mv AT koracksenija carbidopaanactivatorofarylhydrocarbonreceptorsuppressesido1expressioninpancreaticcanceranddecreasestumorgrowth
AT rajasekarandevaraja carbidopaanactivatorofarylhydrocarbonreceptorsuppressesido1expressioninpancreaticcanceranddecreasestumorgrowth
AT sniegowskityler carbidopaanactivatorofarylhydrocarbonreceptorsuppressesido1expressioninpancreaticcanceranddecreasestumorgrowth
AT schniersbradleyk carbidopaanactivatorofarylhydrocarbonreceptorsuppressesido1expressioninpancreaticcanceranddecreasestumorgrowth
AT ibrahimandrewf carbidopaanactivatorofarylhydrocarbonreceptorsuppressesido1expressioninpancreaticcanceranddecreasestumorgrowth
AT bhutiayangzomd carbidopaanactivatorofarylhydrocarbonreceptorsuppressesido1expressioninpancreaticcanceranddecreasestumorgrowth